Compare Entegris Inc (ENTG) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Enveric Biosciences Inc — how do they compare? Entegris Inc trades at $164.6 (market cap $24.78B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.80M). The key difference: Entegris Inc is far larger — about 3644.1× Enveric Biosciences Inc's market cap, and Entegris Inc pays a 0.25% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Enveric Biosciences Inc for 14 Days on average.
| ENTG | ENVB | |
|---|---|---|
Market Cap | $24.78B | $6.80M |
Volume | 2,648,320 | 64,867 |
Sector | Technology | Health |
52-Week High | $184.00 | $10.80 |
52-Week Low | $68.80 | $1.27 |
Typical Hold Time | 41 Days | 14 Days |
Enterprise Value | $27.99B | -$1.49M |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $166.32, down 0.34% on the day, with strong technical momentum showing bullish moving averages and key resistance at $168. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected October 29. Revenue remains stable at $3.2B (2025) with improving net margins from 5.12% (2023) to 7.37% (2025), though valuation ratios appear elevated with P/E at 83.16.
Wall Street maintains strong bullish sentiment with 70% buy ratings and $182.43 consensus price target, representing 9.7% upside. Key risks include high debt levels ($3.98B) and semiconductor industry cyclicality. The upcoming Q3 earnings and November Investor Day will be critical catalysts for near-term direction.
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
